Co-Diagnostics shares are trading higher after the company announced it performed an in silico analysis of the Co-Dx Logix Smart Mpox RUO test to evaluate the possible impact of clade Ib mpox on the test. Results showed that the test should retain full reactivity against mpox strains circulating over the last year, including clade 1b.
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics shares rose after the company announced successful in silico analysis of its Co-Dx Logix Smart Mpox RUO test, confirming its effectiveness against recent mpox strains, including clade 1b.
September 05, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Co-Diagnostics shares increased following the announcement that their Co-Dx Logix Smart Mpox RUO test remains effective against recent mpox strains, including clade 1b, as confirmed by in silico analysis.
The positive in silico analysis results suggest that Co-Diagnostics' test is effective against current mpox strains, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100